<DOC>
	<DOCNO>NCT01619033</DOCNO>
	<brief_summary>This open , parallel group study subject normal renal function compare renal dysfunction .</brief_summary>
	<brief_title>Pharmacokinetics BF2.649 Renal Impairment</brief_title>
	<detailed_description>The pharmacokinetic BF2.649 ( pitolisant ) already well establish several study healthy human , recent pharmacokinetic study give data 12 young healthy volunteer compare 12 elderly subject receive 20mg/day 14 day . The aim study investigate effect renal impairment pharmacokinetics BF2.649 administrate single oral dose 20 mg . The daily dose 20 mg BF2.649 ( pitolisant ) chosen study correspond usual therapeutic dose . Twenty four subject stratify accord renal function use assessment glomerular filtration rate ( GFR ) define MDRD formula follow : - 4 subject 18 75 year age mild impaired renal function define GFR 60 89 ml/min ( STAGE 2 accord international classification chronic kidney disease ) - 4 subject 18 75 year age moderate impair renal function define GFR 30 59 ml/min ( STAGE 3 accord international classification chronic kidney disease ) - 4 subject 18 75 year age severe impaired renal function define GFR 15 29 ml/min ( STAGE 4 accord international classification chronic kidney disease ) - 12 healthy subject normal renal function define GFR &gt; 90 ml/min proteinuria ( &lt; 0.15g/L determined urinalysis ) match impaired renal function subject ethnic group , sex , age ( +/- 5 year ) , BMI ( +/- 20 % )</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>For subject impaired renal function : Subjects 18 75 year old impaired renal function ( MDRD formula 15 89mL/min ) medically stable since 3 month With body mass index ( weight/height2 ) range 18 32 kg/m2 ( inclusive ) For healthy subject : Healthy subject 18 75 year old normal renal function ( MDRD &gt; 90 mL/min ) proteinuria ( &lt; 0.15g/L determined urinalysis ) match impaired renal function subject ethnic group , sex , age ( +/ 5 year ) , BMI ( +/ 20 % ) For impaired renal function subject : History hepatic , cardiovascular ( include conduction disturbance ) psychiatric disorder condition , opinion investigator , would jeopardize safety subject impact validity study result . Evidence liver disease Presence concomitant pathology require intake drug substance know inhibitor inductor CYP enzymes Presence metabolic ionic disorder control adapted treatment Presence significant anemia , nephrotic syndrome Renal transplantation For healthy subject : history renal , cardiovascular , gastrointestinal , hepatic , neurological , endocrine psychiatric disorder surgery put risk opinion investigator . Any treatment within 14 day inclusion , within 5 time elimination halflife drug , whichever long , include treatment could lead inhibition induction CYP enzymes mainly CYP3A4 CYP2D6 exception hormonal contraception menopausal hormone replacement therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Renal impairment</keyword>
</DOC>